Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $32.9 million.

  • ImmunityBio's Prepaid Assets rose 2710.54% to $32.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.9 million, marking a year-over-year increase of 2710.54%. This contributed to the annual value of $23.9 million for FY2024, which is 683.9% down from last year.
  • According to the latest figures from Q3 2025, ImmunityBio's Prepaid Assets is $32.9 million, which was up 2710.54% from $25.5 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Prepaid Assets registered a high of $32.9 million during Q3 2025, and its lowest value of $7.8 million during Q2 2021.
  • Its 5-year average for Prepaid Assets is $22.2 million, with a median of $23.0 million in 2023.
  • Its Prepaid Assets has fluctuated over the past 5 years, first soared by 29454.62% in 2022, then crashed by 3841.38% in 2023.
  • Quarter analysis of 5 years shows ImmunityBio's Prepaid Assets stood at $15.9 million in 2021, then soared by 98.16% to $31.5 million in 2022, then dropped by 18.73% to $25.6 million in 2023, then fell by 6.84% to $23.9 million in 2024, then soared by 38.13% to $32.9 million in 2025.
  • Its Prepaid Assets was $32.9 million in Q3 2025, compared to $25.5 million in Q2 2025 and $21.7 million in Q1 2025.